PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis[1].
PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 hours) exhibits effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 is 2.29 μM[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca2+[1].
Cell Proliferation Assay
| Cell Line: | PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells[1] |
| Concentration: | 0.5 - 100 μM |
| Incubation Time: | 72 hours |
| Result: | Exhibited effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 was 2.29 μM. |
Cell Cycle Analysis
| Cell Line: | MDA-MB-231[1] |
| Concentration: | 1 μM, 2 μM and 4 μM |
| Incubation Time: | 24 hours |
| Result: | Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1. |
Apoptosis Analysis
| Cell Line: | MDA-MB-231[1] |
| Concentration: | 1 μM, 2 μM and 4 μM |
| Incubation Time: | 24, 48 and 72 hours |
| Result: | Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners. |
Western Blot Analysis
| Cell Line: | MDA-MB-231[1] |
| Concentration: | 1 μM, 2 μM and 4 μM |
| Incubation Time: | 48 hours |
| Result: | Increased the expression of Bax, and decreased the expression of Bcl-2 |